IRWD vs. ZNTL, IGMS, CYRX, KURA, BHC, FOLD, CLDX, NVAX, MYGN, and GERN
Should you be buying Ironwood Pharmaceuticals stock or one of its competitors? The main competitors of Ironwood Pharmaceuticals include Zentalis Pharmaceuticals (ZNTL), IGM Biosciences (IGMS), Cryoport (CYRX), Kura Oncology (KURA), Bausch Health Companies (BHC), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Novavax (NVAX), Myriad Genetics (MYGN), and Geron (GERN).
Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking.
Ironwood Pharmaceuticals received 452 more outperform votes than Zentalis Pharmaceuticals when rated by MarketBeat users. However, 65.00% of users gave Zentalis Pharmaceuticals an outperform vote while only 61.09% of users gave Ironwood Pharmaceuticals an outperform vote.
Zentalis Pharmaceuticals has higher earnings, but lower revenue than Ironwood Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Zentalis Pharmaceuticals presently has a consensus price target of $31.67, indicating a potential upside of 166.55%. Ironwood Pharmaceuticals has a consensus price target of $18.40, indicating a potential upside of 192.06%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ironwood Pharmaceuticals is more favorable than Zentalis Pharmaceuticals.
In the previous week, Ironwood Pharmaceuticals had 4 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 14 mentions for Ironwood Pharmaceuticals and 10 mentions for Zentalis Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.43 beat Zentalis Pharmaceuticals' score of -0.19 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.
Zentalis Pharmaceuticals has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.
Zentalis Pharmaceuticals has a net margin of 0.00% compared to Zentalis Pharmaceuticals' net margin of -254.41%. Zentalis Pharmaceuticals' return on equity of -28.45% beat Ironwood Pharmaceuticals' return on equity.
Summary
Ironwood Pharmaceuticals beats Zentalis Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get Ironwood Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ironwood Pharmaceuticals Competitors List
Related Companies and Tools
